Current Oncology Reports

, Volume 12, Issue 6, pp 358–365

Targeted Signal Transduction Therapies in Myeloid Malignancies

Authors

  • Emma Scott
    • Division of Hematology and OncologyUniversity of Pennsylvania
  • Elizabeth Hexner
    • Division of Hematology and OncologyUniversity of Pennsylvania
  • Alexander Perl
    • Division of Hematology and OncologyUniversity of Pennsylvania
    • Division of Hematology and OncologyUniversity of Pennsylvania
Article

DOI: 10.1007/s11912-010-0126-z

Cite this article as:
Scott, E., Hexner, E., Perl, A. et al. Curr Oncol Rep (2010) 12: 358. doi:10.1007/s11912-010-0126-z

Abstract

The myeloid malignancies include the myeloproliferative neoplasms (MPN) including chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). A growing body of evidence documents that these diseases are caused by genetic mutations that constitutively activate tyrosine kinases. They include the BCR/ABL in CML, the V617F JAK2 in Philadelphia chromosome–negative MPN, and the Flt3 ITD and TKD mutations in AML. Trials of the ABL kinase inhibitor, imatinib, have revolutionized the treatment of CML, and there are ongoing studies with other kinase inhibitors in MPN and AML. Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively. It is becoming apparent that although these kinase mutations have similar effects in vitro, each of the diseases has unique features that alter the use of kinase inhibitors in the clinic.

Keywords

Acute myeloid leukemiaMyeloproliferative neoplasmsChronic myeloid leukemiaImatinibNilotinibSignal transductionBCR/ABLJAK2

Copyright information

© Springer Science+Business Media, LLC 2010